Life Sciences Scoop - Clinical Operations
Welcome to the October edition of Life Sciences Scoop - Clinical Operations! Q3 has come to a close and it's been a very exciting few months in the industry. At Warman O'Brien, we were delighted to announce we were Strategic Partners and Sponsors of the Neuro Summit in Lisbon, and also released some great new video content about our US team, which you can watch here: https://bit.ly/WOBUS
🔥 Hot Job of the Week: Medical Director
As always, we'll start the newsletter with the hottest job at the moment, which is a Medical Director position with a unique, small biotech focused CRO. This role will be focused as an SME within one of 6 therapeutic areas (Rheumatology, Endocrinology, Nephrology, Psychiatry, General Medicine or Immunology), and will have a heavy involvement in clinical trial design, business development activities and ensuring patient safety. With a generous package including a base salary between $250k and $350k, this role is fantastic for an MD, Board Eligible professional that is looking to break ground in their clinical career. If you are interested in this role, apply below:
📰 News Section: Stay Informed and Inspired
Life Sciences is such a rapidly evolving market that it can be hard to keep up to date with the latest developments. Here, we've collated some important news stories from the last month to keep you up to scratch!
Moderna plots its course for their next breakthroughs
Moderna, the well known mRNA biotech that led the charge for a COVID vaccine, has unveiled an ambitious roadmap for the development of new products in the near future. Over the next five years, the company intends to launch up to 15 new products, with four slated for release by 2025. Anticipating $8 - 15 billion in respiratory product sales by 2027, Moderna also envisions an additional $10 - $15 billion in annual sales from novel cancer and rare disease treatments expected to debut by 2028.
Recommended by LinkedIn
Nimbus gains traction through $210 million investment round
There's been some really exciting news for Nimbus Therapeutics today as they closed a $210 million private investment round, led by GV (Google Ventures), SR One Capital Management and Atlas Venture. This investment round, while already being one of the biggest of 2023, follow up on a sale of Nimbus' experimental autoimmune medicine to Takeda for a massive $6 billion earlier this year and a previous investment round of $125m last September. To date, Nimbus have raised a huge $427m.Nimbus focuses on developing novel therapies for treatment of cancer, inflammatory and autoimmune conditions and metabolic diseases using small molecule. They utilise some unique technologies to develop these therapies, including machine learning-based predictive modeling approaches.
Pfizer and Ginkgo ink a new RNA deal to develop new therapies
Pfizer have struck a deal with Ginkgo Bioworks, Inc. worth $331 million for a drug discovery partnership focused on RNA medicines. The deal is focused on undisclosed therapeutic area and details are sketchy, but the size of the deal is significant enough to show that Ginkgo are a serious player with the capabilities to make a real difference in the market. They have already signed deals with Merck Group ($490m, August) and Boehringer Ingelheim ($406m, May).
Who Are We?
Warman O'Brien remains a leading global Life Sciences Recruitment partner. Our track record boasts a 90% success rate of CV-to-interview matches, and we proudly partner with pioneering biotechs, pharmas and CROs across the USA, UK, and Europe. I specialize in Clinical Operations across Biotech and Pharma companies in the US. Stay updated with daily news and be the first to apply for the hottest jobs of the week by following me on LinkedIn!
We hope you find our September newsletter informative and engaging. Don't forget to explore our new website, check out the exciting job opportunity of the week, and stay up-to-date with the latest industry developments through our carefully curated news section. Should you require any assistance with recruitment or have any questions, feel free to reach out to us. Together, let's drive innovation and make a positive impact in the Life Sciences Sector!